The Federal Trade Commission has accepted a settlement agreement from The Upjohn Company and Pharmacia Aktiebolag that is designed to preserve competition in the market for drugs for the treatment of colorectal cancer.
Colorectal cancer is the second most common form of cancer.
About 443,000 Americans are diagnosed with the disease every year and, for those patients whose cancer recurs, only 15 percent survive. I inhibitors for colorectal cancer treatment. Pharmacia is formulating its topoisomerase I inhibitor product under a license from the National Cancer Institute, which developed the compound. Upjohn is based in Kalamazoo, Michigan, and Pharmacia is headquartered in Stockholm, Sweden. The merged firm will be the fifth largest pharmaceutical company in the United States.